Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Aimmune Therapeutics News
Aimmune Therapeutics (AIMT -4.8%) is down on below-average volume in reaction to the FDA's review period for AR101 for peanut allergy.
The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is a huge mover today! The stock decreased 4.56% or $1.07 during the last trading
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET. Company Participants.
Aimmune Therapeutics Funding
|2016-11-07||$145.0M||Nestlé Health Scienc||Nestlé Health Science||Article|
|2018-11-29||$98.0M||Undisclosed||Nestlé Health Science||Article|
Aimmune Therapeutics Executive Hires
|2016-04-06||Douglas Sheehy||General Counsel/Secretary||Article|
|2016-06-22||Daniel Adelman||Chief Medical Officer||Article|
|2017-04-14||Eric Bjerkholt||Chief Financial Officer||Article|
|2018-06-12||Jayson Dallas||President and Chief Executive Officer||Article|
|2019-01-21||Andrew Oxtoby||Chief Commercial Officer||Article|